FDA Greenlights HDT Bio's First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease

SEATTLE, Sept. 19, 2025 /PRNewswire/ -- HDT Bio Corporation, a U.S.-based clinical-stage biotechnology company advancing immune-enhancing solutions for global health, biodefense, and oncology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational...